



Australian Government

Department of Health
Therapeutic Goods Administration

Therapeutic Goods Act 1989
Approval under section 42DF for use of restricted representations by
ENT Technologies

I, Leanne McCauley, Delegate of the Secretary to the Department of Health, on receipt of an application from ENT Technologies, have approved under section 42DF of the *Therapeutic Goods Act 1989* (**the Act**) the restricted representations described in paragraph **(A)** below for use in advertisements directed to consumers, for the products identified in paragraph **(B)**:

A)

- *Suitable for asthma patients* (the Suitability Statement); and
- *If you have asthma, please check with your health professional that this medicine is right for you* (the Advisory Statement) with the Advisory Statement prominently displayed and communicated¹ adjacent, or in close proximity to, the Suitability Statement, whenever the Suitability Statement is used in an advertisement.

B)

- “Eze Allergy” (AUST R 310747)

Dated this 9th day of August 2019

Signed electronically

Leanne McCauley
Delegate of the Secretary to the Department of Health
Advertising Compliance Unit
Regulatory Education and Compliance Branch

¹ As the meaning of ‘prominently displayed and communicated’ is set out in the Therapeutic Goods Advertising Code (No.2) 2018